全文获取类型
收费全文 | 83838篇 |
免费 | 5815篇 |
国内免费 | 3155篇 |
专业分类
耳鼻咽喉 | 416篇 |
儿科学 | 1509篇 |
妇产科学 | 1066篇 |
基础医学 | 8774篇 |
口腔科学 | 1689篇 |
临床医学 | 6110篇 |
内科学 | 10574篇 |
皮肤病学 | 2995篇 |
神经病学 | 7370篇 |
特种医学 | 1614篇 |
外国民族医学 | 6篇 |
外科学 | 4956篇 |
综合类 | 9891篇 |
现状与发展 | 3篇 |
一般理论 | 5篇 |
预防医学 | 6310篇 |
眼科学 | 716篇 |
药学 | 18850篇 |
19篇 | |
中国医学 | 6947篇 |
肿瘤学 | 2988篇 |
出版年
2024年 | 181篇 |
2023年 | 1258篇 |
2022年 | 1597篇 |
2021年 | 2954篇 |
2020年 | 2802篇 |
2019年 | 2441篇 |
2018年 | 2289篇 |
2017年 | 2537篇 |
2016年 | 2717篇 |
2015年 | 2825篇 |
2014年 | 4940篇 |
2013年 | 6067篇 |
2012年 | 4708篇 |
2011年 | 5152篇 |
2010年 | 3899篇 |
2009年 | 3768篇 |
2008年 | 3901篇 |
2007年 | 3930篇 |
2006年 | 3466篇 |
2005年 | 3044篇 |
2004年 | 2727篇 |
2003年 | 2341篇 |
2002年 | 1952篇 |
2001年 | 1690篇 |
2000年 | 1512篇 |
1999年 | 1397篇 |
1998年 | 1301篇 |
1997年 | 1238篇 |
1996年 | 1185篇 |
1995年 | 1100篇 |
1994年 | 984篇 |
1993年 | 835篇 |
1992年 | 852篇 |
1991年 | 757篇 |
1990年 | 733篇 |
1989年 | 705篇 |
1988年 | 658篇 |
1987年 | 581篇 |
1986年 | 571篇 |
1985年 | 856篇 |
1984年 | 789篇 |
1983年 | 576篇 |
1982年 | 571篇 |
1981年 | 530篇 |
1980年 | 486篇 |
1979年 | 334篇 |
1978年 | 249篇 |
1977年 | 202篇 |
1976年 | 183篇 |
1975年 | 127篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
81.
Stanislas Grassin‐Delyle Michaela Semeraro Frantz Foissac Naim Bouazza Haleema Shakur‐Still Ian Roberts Jean‐Marc Treluyer Saïk Urien 《Fundamental & clinical pharmacology》2019,33(6):670-678
Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss and death due to bleeding after trauma and post‐partum haemorrhage. One key issue for treatment success is early administration. While usually given intravenously, oral and intramuscular use would be useful in specific circumstances. Therefore, an understanding of TXA pharmacokinetics when given via different routes is valuable. The aim of this study was to perform an individual participant data meta‐analysis of pharmacokinetic studies with TXA given to healthy volunteers via different routes. We searched the following databases: PubMed, Web of Science, Wiley Online Library, Elsevier Science Direct and J‐STAGE. Individual subject data were extracted when available, otherwise arithmetic means were used. A population pharmacokinetic model was developed using nonlinear mixed effect modelling. Seven studies were included in the analysis with data from 10 patients for the IV route, six patients for the IM route and 114 patients for the oral route. The pharmacokinetics was ascribed to a two‐compartment model, and the main covariate was allometrically scaled bodyweight. Oral and IM bioavailabilities were 46 and 105%, respectively. For a 70 kg bodyweight, the population estimates were 7.6 L/h for clearance, 17.9 L for the volume of the central compartment, 2.5 L/h for the diffusional clearance and 16.6 L for the peripheral volume of distribution. Larger well‐designed studies are needed to describe the pharmacokinetics of TXA when given IM or as an oral solution before these can be recommended as alternatives to IV. 相似文献
82.
目的:观察健脾疏肝降脂方治疗非酒精性脂肪肝(NAFLD)肥胖小鼠ALT、AST、FFA及光镜下病理组织学改变,并与壳脂胶囊治疗组比较,观察其疗效。方法:将72只小鼠随机分为模型组、健脾疏肝降脂方高、中、低剂量组、壳脂胶囊对照组和空白组。采用饲养高脂饲料及皮下注射5%CCl4复制NAFLD肥胖小鼠模型,分别以相应药物灌胃6周,检测血清中ALT、AST及FFA的含量,光镜下观察肝组织的脂肪变程度。结果:①各个用药组相比模型组,血清ALT、AST均降低有统计学意义(P<0.01),且中药各浓度组较壳脂胶囊组血清ALT、AST降低,差异有统计学意义(P<0.05); 中药高、中剂量组相比模型组FFA降低,比较有统计学意义(P<0.05); 但与壳脂胶囊组相比,中药各剂量组改善FFA,差异无明显统计学意义(P>0.05)。②光镜可见:各用药组光镜下病理组织改变均较模型组明显,以中、高剂量组较低剂量组小鼠肝细胞脂肪变程度减轻较明显。结论:健脾疏肝降脂方能有效降低NAFLD肥胖小鼠的肝功能、其与浓度无关; 可以降低FFA及改善光镜下肝脏的脂肪变,其有效程度与浓度有一定的关系。 相似文献
83.
目的采用网络药理学和分子对接法分析款冬花在清肺排毒汤治疗新型冠状病毒肺炎(COVID-19)中发挥的作用。方法基于课题组前期研究,确定款冬花中的主要成分。采用SwissTargetPrediction和BATMAN-TCM数据库对款冬花主要化学成分的潜在靶点进行整理;在GenCLiP 3和GeneCard数据库搜索COVID-19相关靶点,运用Cytoscape 3.7.1软件绘制款冬花成分-靶点-疾病网络图;使用String数据库构建靶点PPI网络;通过DAVID数据库进行GO富集分析和KEGG通路富集分析;将各成分与新型冠状病毒(SARS-CoV-2)3CL水解酶和血管紧张素转化酶II(ACE2)进行分子对接。结果款冬花治疗COVID-19的化合物-靶点-疾病网络包含化合物14个、靶点104个、疾病4个。GO功能富集分析得到GO条目444个(P0.05),其中包括生物过程(BP)条目325个、细胞组成(CC)条目44个、分子功能(MF)条目75个。KEGG通路富集筛选得到94条信号通路(P0.05)。分子对接结果显示异绿原酸B(3,4-dicaffeoylquinicacid)和异绿原酸C(4,5-dicaffeoylquinic acid)与蛋白的亲和力要优于瑞德西韦。结论款冬花中主要化合物能通过与SARS-Co V-2 3CL水解酶和ACE2结合,作用于多靶点调节多条信号通路,从而发挥对COVID-19的防治作用。 相似文献
84.
85.
86.
87.
88.
89.
Tau Ming Liew 《Journal of the American Medical Directors Association》2019,20(8):1054.e11-1054.e20
ObjectivesEarly diagnosis of cognitive impairment is increasingly emphasized in the literature to facilitate timely preventive interventions. Although bedside cognitive tests such as the Montreal Cognitive Assessment (MoCA) are widely used for such early diagnostic purposes, they may not have comparable performance to a full neuropsychological battery (FNB) in diagnosing early cognitive impairment. This study investigated whether a small subset of neuropsychological tests can be added on to MoCA to match its performance to that of the FNB in discriminating mild cognitive impairment and dementia (MCI/dementia) from normal cognition.DesignCross-sectional diagnostic study.SettingAlzheimer's Disease Centers across the United States.ParticipantsOlder participants (≥50 years) who completed MoCA and the FNB (N = 9187).MeasuresThe study sample was split into two: the derivation sample (n = 1837) was used to develop a brief neuropsychological battery that best discriminated MCI/dementia (using the best-subset approach with 10-fold cross-validation); while the validation sample (n = 7350) verified its actual performance in discriminating MCI/dementia.ResultsA 3-item neuropsychological battery was identified, comprising MoCA, Benson Complex Figure Recall, and Craft Story 21 Delayed Recall. It had excellent performance in discriminating MCI/dementia from normal cognition (area under the receiver operating characteristic curve [AUROC] 90.0%, 95% confidence interval [CI] 89.2%-90.7%), which was comparable to that of the FNB (AUROC 88.4%, 95% CI 87.6%-89.2%). By contrast, MoCA alone had significantly worse AUROC (86.9%, 95% CI 86.0%-87.7%) than that of the FNB.Conclusions/ImplicationsUsing rigorous methods, this study developed a brief neuropsychological battery that maintained the brevity of a bedside cognitive test, while rivaling the diagnostic performance of an FNB in early cognitive impairment. This brief battery offers a viable alternative when the FNB is needed but cannot be feasibly administered in nonspecialty clinics. It can have a wider health systems effect of improving patients’ access to accurate diagnosis in early cognitive impairment and facilitating timely interventions to delay the progression of cognitive impairment. 相似文献
90.
OBJECTIVES: To assess the effectiveness and safety of additional bedtime H2‐receptor antagonists (H2RAs) in suppressing nocturnal gastric acid breakthrough (NAB) via a systematic review. METHODS: Eligible trials were identified by searching the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 2, 2004), MEDLINE (January 1966–June 2004), EMBASE (January 1980–June 2004) and CINAHL (January 1982–June 2004). Additional hand‐searching was conducted on the proceedings of correlated conferences, eight important Chinese journals and references of all included trials. All randomized controlled trials evaluating H2RAs for the control of NAB were eligible for inclusion. The systematic review was conducted using methods recommended by The Cochrane Collaboration. RESULTS: Only two randomized crossover studies, comprising 32 participants, met the inclusion criteria. Because the design, dosage and duration of the treatments were different between the studies, it was not possible to conduct meta‐analysis. There were no consistent conclusions found between the two included studies in evaluating H2RAs for the control of NAB. CONCLUSIONS: No implications for practice at this stage can be concluded. Appropriately designed large‐scale randomized controlled trials with long‐term follow up are needed to determine the effects of additional bedtime H2RAs in suppressing NAB. 相似文献